

Chapter 136

Fabry Disease

Atul B. Mehta & Catherine H. Orteu

REFERENCES

1. Mehta A, Hughes DA: (updated March 2011) Fabry Disease in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle. 1997–2008. Available at <http://www.genetests.org>
2. Meikle PJ et al: Prevalence of lysosomal storage disorders. *JAMA* **281**:249, 1999
3. Spada M et al: High incidence of later-onset Fabry disease revealed by newborn screening. *Am J Hum Genet* **79**:31, 2006
4. Wilcox WR et al: Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. *Mol Genet Metab* **93**:112, 2008
5. Schaefer E et al: Thirty four novel mutations of the GLA gene in 121 patients with Fabry disease. *Hum Mutat* **25**:412, 2005
6. Garman SC, Garboczi DN: The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. *J Mol Biol* **337**:319, 2004
7. Anderson W: A case of angiokeratoma. *Br J Dermatol* **10**:113, 1898
8. Fabry J: Ein beitrag zur kenntnis der purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). *Arch Dermatol Syph* **43**:187, 1898
9. Orteu CH et al: Fabry disease and the skin: data from FOS the Fabry outcome survey. *Br J Dermatol* **157**:331, 2007
10. Dhoat S et al: Patients with Fabry disease with cutaneous vascular lesions have higher disease severity scores and more multisystem involvement: data from 1354 patients registered on FOS, the Fabry outcome survey. *Br J Dermatol* **161**(Suppl.1):45, 2009
11. Weidemann F et al: Misleading terms in Anderson-Fabry disease. *Eur J Clin Invest* **38**:191, 2008
12. Ramaswami U et al: Clinical manifestations of Fabry disease in children: data from FOS—The Fabry Outcome Survey. *Acta Paediatr* **95**:86, 2006
13. MacDermott KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. *J Med Genet* **38**:750, 2001
14. MacDermott KD, Holmes A, Miners AH: Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. *J Med Genet* **38**:769, 2001
15. Hopkin RJ et al: Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. *Ped Res* **64**:550, 2008
16. Larralde M et al: Fabry disease: a study of 6 hemizygous men and 5 heterozygous women with emphasis on dermatologic manifestations. *Arch Dermatol* **140**:1440, 2004
17. Navarro C et al: Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. *Acta Neuropathol (Berl)* **7**:1, 2006
18. Kanekura T et al: Immunoelectron-microscopic detection of globotriaosylceramide accumulated in the skin of patients with fabry disease. *Br J Dermatol* **153**:544, 2005
19. Orteu CH et al: Fabry disease and angiokeratoma corporis diffusum are not synonymous: Cutaneous vascular lesions and facial features in 100 patients with Fabry disease. *Br J Dermatol* **161**(Suppl.1):46, 2009
20. Ries M et al: Quantitative dysmorphology assessment in Fabry disease. *Genet Med* **8**:96, 2006
21. Cox-Brinkman J et al: Three-dimensional face shape in Fabry disease. *Eur J Hum Genet* **15**:535, 2007
22. Chabas A et al: Mild phenotypic expression of alpha-N-acetylgalactosaminidase deficiency in two adult siblings. *J Inher Metab Dis* **17**:724, 1994
23. Lozano F, Garcia-Talavera R, Gomez-Alonso A: An unusual cause of lymphedema—confirmed by isotopic lymphangiography. *Eur J Vasc Surg* **2**:129, 1988
24. Gemignani F et al: Fabry's disease with familial lymphedema of the lower limbs. Case report and family study. *Eur Neurol* **18**:84, 1979
25. Moffatt CJ et al: Lymphedema: an underestimated health problem. *QJM* **96**:731, 2003

26. Jansen T et al: The significance of lymphedema in fabry disease. *Acta Paediatr Suppl* **447**:117, 2005
27. Gitzelmann G et al: Lymphedema in Fabry disease: Pathology and therapeutic perspectives. *Acta Paediatr Suppl* **451**:122, 2006
28. Amann-Vesti BR et al: Severe Lymphatic micran-giopathy in fabry disease. *Lymphat res Biol* **1**:185, 2003
29. Lohela M et al: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. *Curr Opin Cell Biol* **21**:154, 2009
30. Cable WJ, Kolodny EH, Adams RD: Fabry disease, impaired autonomic function. *Neurology* **32**:498, 1982
31. Hilz MJ et al: Enzyme replacement therapy improves function of C-adelta-, and Abeta-nerve fibers in Fabry neuropathy. *Neurology* **62**:1066, 2004
32. Schiffman R et al: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. *Muscle Nerve* **28**(6):703-710, 2003
33. Lidove O et al: Hyperhidrosis: A new and often early symptom in Fabry disease. International experience and data from the fabry outcome survey. *Int J Clin Pract* **60**:1053, 2006
34. Strutton DR et al: US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: Results from a national survey. *J Am Acad Dermatol* **51**:241, 2004
35. Wasik JS et al: Nailfold capillaroscopy: Specific features in Fabry disease. *Clin Hemorheol Microcirc* **42**:99, 2009
36. Cooke JP, Marshall JM: Mechanisms of Raynaud's disease. *Vasc Med* **10**:293, 2005
37. Mehta A et al: Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. *Eur J Clin Invest* **34**:236, 2004
38. Sodi A et al: Ocular manifestations of Fabry disease: Data from the Fabry Outcome Survey. *Br J Ophthalmol* **91**:210, 2007
39. Hoffman B et al: Gastrointestinal symptoms in 342 patients with Fabry disease: Prevalence and response to enzyme replacement therapy. *Clin Gastroenterol Hepatol* **5**:1447, 2007
40. Linhart A et al: Cardiac manifestations of Anderson Fabry Disease: Results from the International Fabry Outcome Survey. *Eur Heart J* **28**:1228, 2007
41. Rolfs A et al: Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study. *Lancet* **366**:1794, 2005
42. Cole AL et al: Depression in adults with Fabry disease: a common and under-diagnosed problem. *J Inherit Metab Dis* **30**:943, 2007
43. Hauser AC et al: High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. *J Inherit Metab Dis* **28**:715, 2005
44. Magage S et al: Natural history of the respiratory involvement in Anderson-Fabry disease. *J Inherit Metab Dis* **30**:790, 2007
45. Mehta AB, Lewis S, Lavery C: Treatment of lysosomal storage disorders. *BMJ* **327**:462, 2003
46. Schiller PI, Itin PH: Angiokeratomas: An update. *Dermatology* **193**:275, 1996
47. Fleming C et al: Cutaneous manifestations of fucosidosis. *Br J Dermatol* **136**:594, 1997
48. Kanzaki T et al: Angiokeratoma corporis diffusum with glycopeptiduria due to deficient lysosomal alpha-N-acetylgalactosaminidase activity. Clinical, morphologic and biochemical studies. *Arch Dermatol* **129**:460, 1993
49. Rodriguez-Serna M et al: Angiokeratoma corporis diffusum associated with beta-mannosidase deficiency. *Arch Dermatol* **132**:1219, 1996
50. Paller SA: Metabolic disorders characterized by angiokeratomas and neurologic dysfunction. *Neurol clin* **5**:441, 1987
51. Kanitakis J et al: Fucosidosis with angiokeratoma. Immunohistochemical and electron microscopic study of a new case and literature review. *J Cutan Pathol* **32**:506, 2005
52. Albay D et al: Chloroquine- induced lipidosis mimicking Fabry disease. *Mod Pathol* **18**:733, 2005
53. Gil-Mateo M et al: Widespread angiokeratomas and tuberous sclerosis. *Br J Dermatol* **135**:280, 1996
54. Shannon PL, Ford M: Angiokeratomas in juvenile dermatomyositis. *Pediatr Dermatol* **16**:448, 1999
55. Marsden J, Allen R: Widespread angiokeratomas without evidence of metabolic disease. *Arch Dermatol* **123**:1125, 1987
56. Waldek S et al: Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry. *Genetics in Medicine* **11**(11):790-796, 2009
57. Mehta A et al: Natural course of Fabry disease: Changing pattern of causes of death in FOS – Fabry Outcome Survey. *J Med Genet* **46**:548, 2009

58. Eng CM et al: A phase 1/2 clinical trial of enzyme replacement in fabry disease: Pharmacokinetic, substrate clearance, and safety studies. *Am J Hum Genet* 68:711, 2001
59. Thurberg BL et al: Monitoring the 3-year efficacy of enzyme replacement therapy in fabry disease by repeated skin biopsies. *J Invest Dermatol* 122:900, 2004
60. Ross BS, Levine VJ, Ashinoff R: Laser treatment of acquired vascular lesions. *Dermatol Clin* 15:385, 1997
61. Morais P et al: Angiokeratomas of Fabry successfully treated with intense pulsed light. *J Cosmet Laser Ther* 10:218, 2008
62. Pfirrmann G, Raulin C, Karsai S: Angiokeratoma of the lower extremities: successful treatment with a dual-wavelength laser system (595 and 1064 nm). *J Eur Acad Dermatol Venereol* 23:186, 2009
63. Ozdemir M et al: Treatment of angiokeratoma of Fordyce with long-pulse neodymium-doped yttrium aluminium garnet laser. *Dermatol Surg* 35:92, 2009
64. Rockson SG: Diagnosis and management of lymphatic vascular disease. *J Am Coll Cardiol* 52:799, 2008
65. Ram R, Lowe NJ, Yamauchi PS: Current and emerging therapeutic modalities for hyperhidrosis, part 1: Conservative and non-invasive treatments. *Cutis* 79:211, 2007
66. Ram R, Lowe NJ, Yamauchi PS: Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. *Cutis* 79:281, 2007
67. Pope JE: The diagnosis and treatment of Raynaud's phenomenon. *Drugs* 67:517, 2007
68. Coleiro B et al: Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. *Rheumatology (Oxford)* 40:1038, 2001
69. Schiffmann R et al: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA* 285:2743, 2001
70. Eng CM et al: Safety and efficacy of recombinant human α -galactosidase A-replacement therapy in Fabry's disease. *N Engl J Med* 345:9, 2001
71. Hughes DA et al: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase α -alfa. *Heart* 94:153, 2008
72. Mehta AB et al: Evidence of benefit of 5 years of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease —A report from the Fabry Outcome Survey (FOS). *Lancet* 374:1986, 2009
73. Beck M: New therapeutic options for lysosomal storage disorders:enzyme replacement, small molecules and gene therapy. *Hum Genet* 121:1, 2007

